Virus News and Research

Latest Virus News and Research

Antibody-based therapies successfully protect monkeys from deadly Ebola and Marburg viruses

Army scientists have demonstrated, for the first time, that antibody-based therapies can successfully protect monkeys from the deadly Ebola and Marburg viruses. In addition, the animals were fully protected even when treatment was administered two days post-infection, an accomplishment unmatched by any experimental therapy for these viruses to date.

14 Mar 2012

Inovio achieves strong T cell immune responses in PENNVAX-B Phase I HIV study

Inovio Pharmaceuticals, Inc. announced today that it has achieved strong T cell immune responses in a Phase I clinical study of PENNVAX-B, its product for the treatment of the HIV subtype prevalent in North America and Europe, in HIV-positive subjects.

13 Mar 2012

EBV can infect and may also contribute to lymphomas in man's best friend

More than 90 percent of humans have antibodies to the Epstein Barr virus. Best known for causing mononucleosis, or "the kissing disease," the virus has also been implicated in more serious conditions, including Hodgkin's, non-Hodgkin's and Burkitt's lymphomas. Yet little is known about exactly how EBV triggers these diseases.

13 Mar 2012

Medivir initiates two new HPC3001 and HPC3011 phase III trials in HCV

MedivirAB a research based specialty pharmaceutical company focused on infectious diseases announces that its oral, once daily investigational protease inhibitor TMC435, developed by Janssen Pharmaceuticals for the treatment of Hepatitis C virus (HCV), has commenced patient dosing and started screening in two new phase III clinical trials, HPC3001 and HPC3011, respectively.

13 Mar 2012

Scientists at Seattle conference discuss progress, obstacles in fight against HIV/AIDS

"Scientists, stymied for decades by the complexity of the human immunodeficiency virus, are making progress on several fronts in the search for a cure for HIV infections," but "a major stumbling block is the fact that HIV lies low in pools or reservoirs of latent infection that even powerful drugs cannot reach, scientists told the Conference on Retroviruses and Opportunistic Infections, one of the world's largest scientific meetings on HIV/AIDS," in Seattle last week, Reuters reports.

13 Mar 2012

Study addresses how human body controls gamma-herpesviruses

New research from the Trudeau Institute addresses how the human body controls gamma-herpesviruses, a class of viruses thought to cause a variety of cancers. The study, carried out in the laboratory of Dr. Marcia Blackman, awaits publication in The Journal of Immunology.

13 Mar 2012

Partner reduction strategies essential to reversing spread of HIV

"The rising enthusiasm for providing more medicines threatens to come at the expense of promising initiatives for preventing HIV infections in the first place -- initiatives that could save many lives, with less money," Craig Timberg, the newspaper's deputy national security editor, and Daniel Halperin, an epidemiologist at the University of North Carolina, write in this Washington Post opinion piece.

12 Mar 2012

U-M to research into treatment for hepatitis C

The Greenview Foundation has announced a gift of $57,000 to the University of Michigan Health System to support research on a treatment for hepatitis C.

12 Mar 2012

Top-line results from Inviragen's INV21 Phase 1 trial on HFMD

Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company's highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71.

12 Mar 2012

Asahi Kasei to acquire ZOLL

Asahi Kasei Corporation, and ZOLL Medical Corporation today jointly announced that Asahi Kasei, Japan's leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, has entered into a definitive merger agreement with ZOLL, a manufacturer of resuscitation and critical care devices and related software solutions, pursuant to which Asahi Kasei will acquire ZOLL for approximately $2.21 billion.

12 Mar 2012

Common sexually transmitted bacterial infection more than doubles risk of HIV

A common sexually transmitted bacterial infection more than doubles the risk of HIV infection in African women, according to a study by researchers at RTI International.

11 Mar 2012

New vaccination strategy may effectively eradicate HIV-1 infection

In what may prove to be a major step forward for the treatment of HIV-1 infection, scientists have discovered an effective way to eliminate a notoriously persistent form of the virus that does not respond to current therapies. The research, published online by Cell Press on March 8th from the journal Immunity, describes a vaccination strategy that may be essential for successful eradication efforts and should therefore be considered for future clinical trials.

9 Mar 2012

GenMark Diagnostics fourth quarter revenues increase to $2.0M

GenMark Diagnostics, Inc. today reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2011. The Company will release its full financial statements and related disclosures along with its Form 10-K filing for the period ending December 31, 2011 upon completion of its independent audit, which includes the Company's first Sarbanes-Oxley audit of internal controls, by March 15, 2012.

9 Mar 2012

HDAC inhibitors flush latent HIV infection from hiding

A team of researchers at the University of North Carolina at Chapel Hill have successfully flushed latent HIV infection from hiding, with a drug used to treat certain types of lymphoma.

9 Mar 2012

Infection with M. genitalium may double African women's HIV risk

A common sexually transmitted bacterial infection more than doubles the risk of HIV infection in African women, reports a study in the March issue of AIDS.

9 Mar 2012

Enzo Biochem to unveil data on AmpiProbe HCV assay at ESCMID meeting

Enzo Biochem Inc. announced today that the company will present for the first time peer-reviewed data on detection of hepatitis C virus (HCV) using its novel AmpiProbe technology platform, which provides low cost and high sensitivity real-time nucleic acid amplification assays.

9 Mar 2012

Researchers identify specific gene linked with throat cancer

Researchers at King's College London and Hiroshima University, Japan, have identified a specific gene linked to throat cancer following a genetic study of a family with 10 members who have developed the condition.

8 Mar 2012

MTPC, Medicago partner to develop and commercialize three new vaccines

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the establishment of a strategic alliance with Mitsubishi Tanabe Pharma Corporation (MTPC) through the execution of a Master Research Collaboration Agreement.

6 Mar 2012

Leading AIDS experts issue new HIV guidelines

Leading AIDS experts at Johns Hopkins and other institutions around the world have issued new guidelines to promote entry into and retention in HIV care, as well as adherence to HIV treatment, drawn from the results of 325 studies conducted with tens of thousands of people infected with HIV, the virus that causes AIDS.

6 Mar 2012

Rep. Sensenbrenner sends 'fact-finding letter' to White House science adviser about bird flu studies

"Representative Jim Sensenbrenner (R-Wis.), a former head of the House committees on science and the judiciary, and currently vice chair of the House Committee on Science, Space, and Technology, last week sent a 'fact-finding letter' to White House science adviser John Holdren, asking pointed questions about how the U.S. government has handled the controversy" surrounding two studies that showed how H5N1 bird flu virus could be manipulated to become transmissible among ferrets, a model for humans, "and questioning whether it should have funded the two flu studies," ScienceInsider reports.

6 Mar 2012